Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Primary completion
- Jan 2028
- Modality
- Peptides
- Countries
- 13
01
Overview
A Phase 3 trial of eloralintide in obesity, type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Dec 2025; status: recruiting.
02
Drugs
eloralintide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07282600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282600.